Bank of Montreal
NBIX icon

Bank of Montreal’s Neurocrine Biosciences NBIX Stock Holding History

Bank of Montreal’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,800
Closed -$3.28M – 4202
2023
Q3 		$3.28M Buy
+28,800
New +$3.03M ﹤0.01% 1468

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of Montreal's NBIX Position: Q2 2026 in Review

Bank of Montreal increased its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, buying an estimated $696K and bringing the position to 35,697 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

Bank of Montreal first reported a position in NBIX in Q2 2014 and has held it in 46 quarters since. The position peaked at $71.1M in Q3 2021. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bank of Montreal held 35,697 shares of Neurocrine Biosciences worth $6.02M as of Q2 2026.
  • Bank of Montreal bought 4,694 Neurocrine Biosciences shares in Q2 2026, an estimated $696K.
  • Neurocrine Biosciences made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1316 holding.
  • Bank of Montreal first reported a position in Neurocrine Biosciences in Q2 2014 and has held it in 46 quarters since.
  • Bank of Montreal's Neurocrine Biosciences position peaked at $71.1M in Q3 2021.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.